Updated on 30 January 2015
Cancer Immunotherapy includes cancer vaccines as a form of treatment
Singapore: National Cancer Centre Singapore (NCCS) has launched a clinical trial of a new cancer vaccine, a form of cancer immunotherapy, to boost the body's immune cells to attack a target protein in cancer cells administered to human patients.
The vaccine is developed by a US biotech company, MicroVAX.
Cancer Immunotherapy includes cancer vaccines, a form of treatment aimed at stimulating the body's immune cells to attack a target protein on cancer cells. This particular cancer vaccine encodes one of the most common proteins, MUC-1 that is expressed on many cancers, including ovarian, breast, prostate, colon, pancreas and lung cancer, but not expressed on normal cells.
The Singapore Clinical Research Institute (SCRI), a wholly-owned subsidiary of MOH Holdings, sponsored this clinical trial providing support that included project oversight, study drug importation, quality assurance and providing the medical expertise required in conducting a cancer trial.
Dr Toh Han Chong, principal investigator of the phase I clinical trial, NCCS,said, "What makes this vaccine unique is that MUC-1 is attached to a protein that is intentionally designed to further enhance and boost the efficiency and power of the body's immune system." This protein is called CD40-ligand (CD40L), to form a construct called MUC-1+CD40L.